FDA approves GSK’s Blenrep for advanced multiple myeloma
pharmaphorum
AUGUST 6, 2020
Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein commonly found on the surface of the malignant B-cells that cause the disease.
87 
Let's personalize your content